Lexology February 18, 2021
Nossaman LLP

Congress and the Biden Administration are grappling with an economic stimulus bill that will touch many segments of American life, including health care, if it passes in the Senate. This has many clients wondering what impact the Biden Administration will have on the healthcare sector from a regulatory perspective. Early indications point to a focus on four issues that continue to resound: the Affordable Care Act (“ACA”), COVID-19-related regulatory relief, lowering prescription drug prices and restricting the occurrence of surprise billing.

The ACA

To strengthen the ACA, the Biden Administration has proposed three key steps: (1) capping the amount each household spends on insurance premiums at 8.5% of household income; (2) increasing subsidies to low-income Americans; and (3) initiating an...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: ACA (Affordable Care Act), Biotechnology, Congress / White House, Govt Agencies, Healthcare System, Insurance, Medicaid, Payer, Pharma, Pharma / Biotech, Pricing / Spending, Public Exchange, Public Health / COVID
How Donald Trump Is Reshaping Global Health
AAFP’s prescription for primary care success in 2025
Executive Orders Suggest Swift Pivot in Managed Care and Health Policy
InnovationRx: The Impact Of Trump’s Withdrawal From The WHO And His Other Healthcare Orders
Medicare Negotiations Could Fuel, Not Stifle, Innovation

Share This Article